title: [Studies on the effects of adjuvant chemotherapy on the survival period of patients with colorectal carcinoma].
abstract: One hundred and eighty nine patients who had undergone curative resection of colorectal cancer were treated with a prospective randomized controlled adjuvant chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432. One hundred and thirty five patients with Dukes' B and Dukes' C carcinoma were valid for evaluation. Effects of the therapy were estimated by cumulative survival rate. There was no significant survival difference in colonic carcinoma and Dukes' B rectal carcinoma between the treated and control groups. But there was an advantage in two and three years survival for the chemo-immunotherapy in Dukes' C rectal carcinoma (p less than 0.1). Examining the survival rate of Dukes' C rectal carcinoma for each combination of therapeutic agents, the patients treated with Tegafur and ADM had the most favorable survival rate, the patients treated with Tegafur alone had the next favorable one, the patients treated with Tegafur and MMC had the lowest one. The administration of MMC during operation was less effective than the post operative administration in Dukes' C rectal carcinoma.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects; D010844:Picibanil / Q000008:administration & dosage; D011446:Prospective Studies; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D005641:Tegafur; D010844:Picibanil; D016685:Mitomycin; D004317:Doxorubicin